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ABSTRACT 
[11C]Preladenant was developed as a novel PET ligand for the adenosine A2A 
receptors (A2ARs). The present study aims to evaluate the suitability of 
[11C]preladenant-PET for the quantification of striatal A2ARs and the assessment of 
A2AR occupancy in the conscious monkey brain.  
Methods: [11C]Preladenant was i.v. injected into conscious monkeys (n=4, 18 PET 
scans) and a 91-min dynamic scan was started. Arterial blood samples in 
combination with metabolite analysis were obtained during the scan to provide the 
input function for kinetic modelling. The distribution volume (VT) was obtained by 
kinetic modeling with a 2-tissue compartment model (2TCM). The simplified 
reference tissue model (SRTM) with selected reference regions (cerebellum, 
cingulate, parietal cortex, and occipital cortex) was tested to estimate the binding 
potential (BPND) in A2AR-rich regions. BPND obtained from the SRTMs was 
compared with distribution volume ratio (DVR)-1. The effects of blood volume, 
blood delay, and scan duration on BPND and DVR-1 were investigated. VT and BPND 
were also obtained after preblocking with unlabeled preladenant (1 mg/kg), A2AR-
selective KW-6002 (0.5-1 mg/kg) and non-selective adenosine receptor antagonist 
caffeine (2.5-10 mg/kg). A2AR occupancy was studied with caffeine blockade. 
Results: Regional uptake of [11C]preladenant was consistent with the distribution 
of A2ARs in the monkey brain, with the highest uptake in putamen, followed by 
caudate, and the lowest uptake in cerebellum. Tracer kinetics was well described 
by the 2TCM with a lower constraint on k4 to stabilize fits. Highest VT was 
observed in A2AR-rich regions (~5.8-7.4) and lowest value in cerebellum (~1.3). 
BPND values estimated from the SRTM with different scan durations were 
comparable, and were in agreement with DVR-1 (~4.3-5.3 in A2AR-rich regions). 
Preladenant preinjection decreased the tracer uptake in A2AR-rich regions to the 
level of the reference regions. Caffeine pretreatment reduced the tracer uptake in 
striatum in a dose-dependent manner.  
Conclusion: [11C]Preladenant PET is suitable for non-invasive quantification of 
A2ARs and assessment of A2AR occupancy in A2AR-rich regions in the monkey 
brain. SRTM using cerebellum as the reference tissue is the applicable model for 
A2AR quantification. 
Key words: adenosine A2A receptors, PET, [11C]preladenant, pharmacokinetic 
modeling, monkey. 
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INTRODUCTION 
The adenosine A2A receptor (A2AR) has drawn much attention in the past decades, 
because it has been implicated in brain disorders such as depression 15, 
Huntington’s disease (HD) 14, Alzheimer’s disease (AD) 34, and Parkinson’s 
disease (PD) 10. A2AR inhibition could alleviate Parkinson’s symptoms without 
exacerbating levodopa-induced dyskinesia 174. Furthermore, A2AR blockade was 
found to be neuroprotective in animal models of AD 21 and HD 175. Consequently, 
the A2AR has been studied as a potential target for CNS disorders, although the 
mechanism by which the receptor is involved in these diseases is still largely 
unknown. Several A2AR antagonists are tested in clinical trials as anti-parkinsonism 
drugs 27. 
Positron emission tomography (PET) with a suitable A2AR radioligand provides a 
unique opportunity to study A2AR availability and function in vivo. This is 
exemplified by the in vivo imaging studies of the PD brain with A2AR radioligands 
[11C]SCH442416 176 and [11C]TMSX 177. In addition, A2AR availability was 
assessed with [11C]TMSX in secondary progressive multiple sclerosis (SPMS) 57. 
Differences were found in striatum between the drug naïve and levodopa treated 
PD patients, and in normal appearing white matter between SPMS patients and 
healthy volunteers. However, due to the unfavorable properties of the radioligands, 
such as low target-to-non-target ratio and high uptake in brain regions with 
negligible levels of A2ARs 55,176,177, the results were difficult to interpret, and 
therefore the usefulness of PET imaging with A2AR radioligands is still to be 
proven.  
We have recently synthesized [11C]preladenant 106, an A2AR antagonist with high 
affinity (Ki=1.1 nM for human A2AR) and selectivity (>1000 fold selective for 
A2ARs over other adenosine receptors) towards A2AR 88. PET imaging in rats 
showed a high uptake of [11C]preladenant in striatum and low uptake in extra-
striatal regions, which was in agreement with cerebral A2AR distribution 2,106,178.  
Based on the encouraging results from the rodent studies, here we further evaluated 
[11C]preladenant in conscious monkeys as a prelude towards first-in-human PET-
studies. We characterized the pharmacokinetic properties of the tracer with kinetic 
modeling. Furthermore, we studied the striatal A2AR occupancy by the non-
selective adenosine receptor antagonist caffeine. 
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MATERIALS AND METHODS 
Materials 
Lithium aluminum hydride (1.0 M in tetrahydrofuran (THF)) was purchased from 
ABX advanced biochemical compounds (Radeberg, Germany). Dimethyl sulfoxide 
(DMSO) and polyethylene glycol 400 (PEG400) were obtained from Aldrich 
(Milwaukee, WI, USA). N,N-dimethylacetamide (DMAA) was purchased from 
Nacalai Tesque (Kyoto, Japan) and Tween 80 from Wako Pure Chemical Industries 
(Osaka, Japan). (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dhydro-1H-
purine-2,6-dione (KW-6002) was purchased from Axon Medchem BV (Groningen, 
The Netherlands). Caffeine was purchased from Sigma (St. Louis, MI, USA). 2-(2-
Furanyl)-7-[2- [4- [4- (2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl] 7H-pyrazolo 
[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine (preladenant) was purchased from 
Chemscene, LLC (Monmouth Junction, NJ, USA). Sterile saline was from Otsuka 
Pharmaceutical (Tokyo, Japan). 
Blocking agents preparation 
A preladenant solution with a concentration of 2 mg/mL was prepared as follows: 
2070 µL of DMSO and 230 µL of Tween 80 were added to a vial containing 23 mg 
preladenant, and this solution was diluted 4 fold with sterile saline. 
A KW-6002 solution with a concentration of 0.5 mg/mL was prepared as follows: 
50 µL of DMAA and 525 µL of PEG400 were added to a vial containing 0.5 mg 
KW-6002, vortexed for 1 min, mixed with 425 µL of sterile saline, and then 
sonicated for 30 min. 
Caffeine solutions with concentration of 2.5, 5.0, and 10 mg/mL were prepared by 
dissolving 25, 50, and 100 mg of caffeine in 10 mL of sterile saline. 
Synthesis of [11C]preladenant 
Carbon-11 (11C) was produced by proton bombardment (18 MeV, 20 µA) of N2 
using a cyclotron (HM-18, Sumitomo Heavy Industry, Tokyo, Japan) at 
Hamamatsu Photonics PET center and obtained as [11C]O2. [11C]O2 was transferred 
under N2 flow (400 mL/min) from a target chamber into the reaction vessel 
containing 0.5 mL of 0.1 M lithium aluminum hydride/ THF solution cooled at -15 
°C with a compressed air blower. Immediately after carboxylation, the reaction 
vessel was heated to evaporate THF at 120 °C under a N2 flow of 400 mL/min. 
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After removal of THF, 0.5 mL of hydroiodic acid was added. The solution was 
heated at 120 °C for 1-2 min under N2 flow to transfer the [11C]methyl iodide 
through a Ascarite II and diphosphorus pentoxide column into the another reaction 
vessel containing 1 mg of precursor (O-desmethyl preladenant) and 10 mg of 
potassium hydroxide powder in 0.3 mL DMSO solution at room temperature. After 
[11C]methyl iodide was collected in the precursor solution, the reaction vessel was 
heated at 40 °C for 3 min. After the reaction, 0.2 mL of 0.1 N hydrochloric acid 
was added to the vessel, and the reaction mixture was injected into a preparative 
high performance liquid chromatography (HPLC) system. The HPLC column was 
YMC-Pack C18Pro, 10 mm in inner diameter x 250 mm in length (YMC, Kyoto, 
Japan). The product was eluted with acetonitrile/30 mM ammonium acetate (4/6) at 
a flow rate of 6 mL/min and the radioactive peak corresponding to the retention 
time of the product was collected into an evaporation flask. The eluent was 
evaporated and the residue was re-dissolved with 5 mL of saline containing 0.1% 
Tween 80, and the solution was filtered through a 0.22 µm filter for injection. The 
total synthesis time was 25-29 min. 
Chemical and radiochemical analysis of [11C]preladenant were performed by HPLC 
in a system consisting of a Finepak SIL C18-S column (4.6 mm in inner diameter x 
150 mm in length, Jasco, Tokyo, Japan), using acetonitrile/30 mM ammonium 
acetate/acetic acid (500/500/2) as a mobile phase at a flow rate of 2 mL/min. 
Animals  
Animals were maintained and handled in accordance with the recommendations of 
the US National Institutes of Health and the guidelines of the Central Research 
Laboratory, Hamamatsu Photonics. All experiments were approved by the Ethical 
Committee of the Central Research Laboratory, Hamamatsu Photonics (HPK-
2014-12). Four young male rhesus monkeys (Macaca mulatta) weighing from 5.0 
to 8.5 kg were used for the PET measurements (baseline n=7; pretreatment with 
caffeine n=3; pretreatment with 1 mg/kg preladenant n=3; pretreatment with 0.5 
mg/kg KW-6002 n=4 (2 without blood sampling); pretreatment with 1 mg/kg KW-
6002 n=1) in a conscious state. Each blocker was intravenously injected 30 min 
before injection of [11C]preladenant. T1-weighted magnetic resonance images 
(MRI) of the monkeys were obtained with a 3.0 T MR imager (Signa sExcite HDxt 
3.0 T, GE Healthcare Japan, Tokyo, Japan). MR images were reconstructed into a 
256x256x178 matrix, with a voxel size of 0.4x0.4x0.7 mm. 
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PET measurements  
After overnight fasting, a venous cannula for PET ligand and/or blocker injection 
was inserted in one inferior limb and an arterial cannula for blood sampling was 
inserted in the other inferior limb. The PET scan was performed using an animal 
PET scanner (SHR-7700, Hamamatsu Photonics, Hamamatsu, Japan) 179. After a 
transmission scan using a [68Ge]-[68Ga] rotation rod source, a 91-min dynamic 
acquisition was started at the time of [11C]preladenant (~1 GBq) injection. Arterial 
blood samples were obtained manually over the acquisition. Blood and plasma 
were separated by centrifugation. The radioactivity in blood and plasma samples 
was measured using a well-counter (1480 WIZARD, Perkin Elmer, Waltham, MA, 
USA). For metabolite analysis, ethanol was added to plasma samples at 16 and 40 
s, and 1, 6, 10, 30, 45, 60, 75, and 90 min post injection (sample/ethanol=1/2, v/v). 
The samples were centrifuged and the obtained supernatants were developed on the 
thin-layer chromatography (TLC) plates (TLC Silica gel 60 F254, Merck, 
Darmstadt, Germany) with a mobile phase of chloroform/methanol (9/1, v/v). At 
each sampling time point, the ratio of radioactivity in the unmetabolized fraction to 
that in total plasma (metabolites plus intact tracer) was determined using a 
phosphoimaging plate (FLA-7000, Fuji Film, Tokyo, Japan). The metabolite 
corrected plasma curves were used as input function for tracer quantification.  
PET data analysis 
Dynamic PET data were histogrammed into 49 frames (6×10, 6×30, 12×60, and 
25×180 s). The frames were reconstructed by filtered back projection with a 
Hanning filter of 4.5 mm full width at half maximum and corrected for attenuation, 
scatter, and random coincidences. All images contained 100x100x20 voxels with a 
voxel size of 1.2x1.2x3.6 mm. Individual PET and MRI were co-registered. 
Volumes of interest (VOIs) were drawn manually on the individual MR images, 
using regional information from BrainMaps.org 180 as anatomical reference. MRI 
derived VOIs were superimposed on the co-registered PET images to extract time-
activity curves (TACs) for kinetic analysis. TACs were normalized to body weight 
and injected activity to yield standardized uptake values (SUVs). 
Tracer kinetic modeling 
Tracer kinetics were quantified with PMOD software (version 3.5, PMOD 
Technologies, Zürich, Switzerland). The fractional blood volume (VB) in the brain 
was either fixed to 0%, 3%, or 5% or used as a fit parameter to assess the effect of 
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blood volume on kinetic parameters. The blood delay was either fixed to 0, or used 
as fit parameter. In addition, to stabilize kinetic model fits we explored both fitting or 
fixing k4 for several reference regions (i.e., regions showing no or minimal specific 
binding). In case of fixing, k4 was set to 0, 0.005, 0.011, 0.02, or 0.04 min-1.  
A mono-exponential function was fitted to the intact tracer fraction over time. A 
standard 2-parameter (K1, k2) 1-tissue compartment model (1TCM) and a 4-
parameter (K1, K1/k2, k3, k4) 2-tissue compartment model (2TCM) with and without 
VB using a metabolite corrected plasma input function were used to fit TACs. The 
effects of variation in VB, blood delay, reference region, k4, and scan duration on 
model fits were judged by Akaike information criterion (AIC) and by the observed 
kinetic parameters (i.e., distribution volume (VT), non-displaceable distribution 
volume (VND), distribution volume ratio (DVR)-1, and non-displaceable binding 
potential (BPND)). BPND in striatum was obtained by = 	 1	(= / − 1) 59 
as well as the non-invasive simplified reference tissue model (SRTM). The 
invasive- and non-invasive model-derived BPND values were compared, using 
DVR-1 with full scan length of 91-min as the gold standard. Cerebellum, cingulate, 
parietal cortex, and occipital cortex were tested as reference regions. Striatum was 
used as the target region in all data analyses. The test-retest variability (TRV) was 
compared between models and reference regions. TRV was calculated as  =
2 × , − ,/(, + ,)  or  = 2 ×
, − ,/(, + ,). 
A2AR occupancy by caffeine 
Three PET scans after administration of 2.5, 5, and 10 mg/kg of caffeine were 
performed with blood sampling as described above, whereas blood sampling 
was not acquired for scans with caffeine doses of 5 and 10 mg/kg. Receptor 





The Wilcoxon signed rank test was used to assess the difference in plasma activity 
and intact tracer fraction between baseline and A2AR-blocker pretreatment, the 
effects of A2AR-blocker pretreatment on VT, and the difference in AIC between 
1TCM and 2TCM. A Bland-Altman plot (difference (∆) vs. mean) was used to 
judge the agreement in BPND and DVR-1. ∆ (%) was computed as ∆		= 2 × 100 ×
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 	 = 	 1

/  = 	 1

. A probability value (p)< 0.05 was 
considered to be statistically significant.  
RESULTS 
Kinetics of [11C]preladenant in plasma 
Figure 5.1 shows the plasma clearance and metabolic radioactivity profile of 
[11C]preladenant during the 91-min scan. KW-6002 and preladenant pretreatment 
did not significantly alter tracer metabolic rate (Figure 5.1B), but significant 
(p<0.05) effects of these compounds were observed on plasma clearance, resulting 
in significantly higher plasma radioactive levels between 24 and 40 seconds post 
injection than at baseline (Figure 5.1A). The tracer metabolic pattern could be 
fitted with a mono-exponential function with 32±7% of radioactivity in plasma 
consisting of intact tracer at 90 min post injection. The metabolite-corrected plasma 
curve at baseline was well described with a bi-exponential function, with a t1/2α of 
0.15±0.03 min, and t1/2β of 6.86±2.19 min. 
 
Figure 5.1 Kinetics of [11C]preladenant in monkey plasma. (A) Time course the total activity in 
plasma at baseline and after blocker pretreatment. The insert shows the first 3 min of the plasma 
kinetics. (B) Parent fraction in plasma at baseline and after blocker pretreatment. Error bars indicate 
standard deviation. *p<0.05. 
Tracer kinetic modeling 
The 2TCM fitted the data better than the 1TCM, with significantly (p<0.001) lower 
(~2-19%) AIC values for all VOIs and visually better agreement between the fitted 
curves and the experimental data (for clarity, only 2TCM fits are shown in Figure 
5.2A). Therefore, the 2TCM was used to quantify tracer kinetics. Variation in the 
VB, blood delay, and k4 value in reference regions did not substantially affect AIC 
values, as only 0-9% difference was found between various fits. Still, best fits 
(smaller AIC) were obtained when VB was either fixed to 5% or included as fit 
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parameter, blood delay was included as fit parameter, and the reference region k4 
was either fixed to 0.011 min-1 or included as fit parameter.  
 
Figure 5.2 (A) Representative time activity curves (TACs) and 2TCM fits of striatum, putamen, 
caudate, and cerebellum at baseline. (B) TACs of striatum and cerebellum after preladenant (1 mg/kg) 
pretreatment. 
The non-displaceable distribution volume (VND) was estimated from the total 
distribution volume (VT) of a reference region (i.e., cerebellum) at baseline and a 
target region (i.e., striatum) with A2AR binding sites completely blocked with 
preladenant. The effect of different VB and k4 values on estimated VND was 
analyzed. The VB has little effect on both VND and VT as <10% difference was 
found with various VB values. The effect of k4 on VND is shown in Figure 5.3. The 
range of fit values for k4 was chosen based on an average cerebellar k4 value of 
0.011 min-1 (17% coefficient of variation (COV)) estimated by 2TCM from 5 out 
of 7 baseline scans. The excluded 2 cases provided very low estimates on K4 
(0.0031 and 0.0056 min-1), resulting in upward biased VND values of 3.1 and 2.6, 
respectively, which were considered outliers (as shown by the boxplots in 
Supplementary figure 5.1).  
Indeed, when k4 was small (0.005 min-1) or without constraint, VND seems to be 
overestimated in 1 or 2 cases at baseline. 2TCM with k4 between 0.011 and 0.04 
min-1 estimated VND values within an acceptable range (i.e., 0<VND<2), whereas 
larger fixed k4 values resulted in somewhat lower VND. 
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  Next, we compared the impact of 2TCM parameters, such as VB (fixing to 5% or 
as fit parameter), blood delay (no delay or as fit parameter), and k4 constraints 
(k4=0.011 and 0.02 min-1, k4≥0.01 min-1, or as fit parameter), on striatal specific 
binding values using DVR-1 derived from VT, striatum/VND, cerebellum-1 (Figure 5.4A). 
The results show that the data points were more scattered with unconstrained k4, 
whereas a lower degree of dispersion was observed when k4≥0.01 min-1. As k4 
negatively correlated to VND (Figure 5.3), DVR-1 calculated with k4 fixed to 0.02 
min-1 was ~35% larger than DVR-1 calculated with k4 fixed to 0.011 min-1 (k4=0.02 
min-1 5.7±1.4 vs. k4=0.011 min-1 4.2±1.2). Other factors like blood delay and VB 
showed small impact on DVR-1 estimates (Figure 5.4A). Therefore, VT and VND at 
baseline and under receptor saturation conditions were estimated by fitting VB and 
blood delay to allow for variation in delay and VB between animals and 
experiments, but with k4 being constrained ≥0.01 min-1 to stabilize the fits. The 
results are presented in Figures 5.4B and C. VT values were 5.8-7.4 in A2AR-rich 
regions and 1.3-1.6 in reference regions at baseline.  
Preladenant pretreatment significantly (p<0.001) reduced the VT in A2AR-rich 
regions to ~1.1, which was comparable with VT in reference regions (~1.0). 
However, the pretreatment with blockers also reduced the VT in reference regions 
by 27-33% (Figure 5.4C), albeit the difference didn’t reach statistical significance. 
Due to the animal welfare issues, KW-6002 pretreatment was unable to achieve 
complete A2AR-blockade (Figure 5.4C). A dose of 1 mg/kg i.v. KW-6002 resulted 
in adverse effects (the monkey lost its consciousness for a while) and therefore 
higher doses were not tested. In addition to cerebellum, we evaluated cingulate, 
Figure 5.3 Effect of k4 on VND. VND was obtained 
as VT in cerebellum from 7 baseline scans and as 
VT in striatum from 3 scans with preladenant 
preblocking. Horizontal lines represent the mean of 
10 scans. MK = monkey. 
Supplementary figure 5.1 Tukey’s 
boxplots of the effect of k4 on VND. VND 
was obtained as VT in cerebellum from 7 
baseline scans and as VT in striatum from 3 
scans with preladenant preblocking. 
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occipital cortex, and parietal cortex as reference regions to predict striatal BPND, for 
the reason that VT values in these regions are comparatively low and stable (Figure 
5.4B). 
 
Figure 5.4 (A) Effect of blood volume, blood delay, and cerebellar k4 on DVR-1; and a comparison in 
BPND between SRTM with different scan durations. The values were obtained using cerebellum as the 
reference region. (B) VT in striatum and reference regions at baseline. Horizontal lines represent the mean of 
7 baseline scans. (C) VT in striatum and reference regions after blocker pretreatment. Solid horizontal lines 
represent the mean of 3 preladenant preblocking scans (blue), and 3 KW-6002 preblocking scans (red, 
reference regions only). Dotted horizontal lines represent the mean of 7 baseline scans (reference regions 
only). MK = monkey, ParietalCtx = parietal cortex, OccCtx = occipital cortex. 
BPND values obtained from the non-invasive SRTM with various reference regions 
as input were in agreement with DVR-1 in general (Figure 5.4A and Figure 5.5), 
with a positive bias of 20 ± 17% when k4 was constrained to above 0.01 min-1. 
Models with cerebellum as the reference region displayed the highest BPND in 
A2AR-rich regions, being ~5.3 (23% COV) in putamen, and ~4.3 (25% COV) in 
caudate. In comparison with cerebellum, parietal cortex as the reference region 
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estimated slightly lower (8%) BPND but higher test-retest reproducibility, showing a 
TRV value of 22% whereas 29% was calculated using cerebellum as the reference 
region. Other reference regions estimated low BPND values with low test-retest 
reproducibility, therefore, these regions are less optimal reference regions to 
quantify tracer kinetics in striatum. The between-subject variability for VT and 
BPND was comparable, being 11-30% COV. TRV was larger for VT and DVR-1 
calculated with the 2TCM, being 31-43%, in comparison with 22-29% TRV for 
BPND determined with the SRTM. 1 mg/kg preladenant preinjection reduced the 
BPND values in target regions to ~0, indicating a complete blockade. Pretreatment 
with KW-6002 resulted in decreased tracer uptake in striatum in all cases, with 
BPND values of 1.0 at 1 mg/kg (n=1), and 2.0 ± 0.7 at 0.5 mg/kg (n=3). In 1 case, 
no effect of 0.5 mg/kg KW-6002 was observed, as the BPND in this animal was 7.4.  
 
Figure 5.5 (A) Striatal BPND estimates from DVR-1 (2TCM) and SRTM, using cerebellum, cingulate, 
parietal cortex and occipital cortex as the reference regions. The values were obtained from 7 baseline 
scans. Horizontal lines represent median with interquartile range. (B) Same data sets as (A) but 
presented as Bland-Altman plot of the difference (∆) between BPND and DVR-1 against the means of 
BPND and DVR-1. The area between the dotted lines represents the 95% confidence interval. 
∆	%
 	 2  100   	 = 	 1

/  = 	 1

 . ParietalCtx = parietal cortex, 
OccCtx = occipital cortex. Avg = average. 
Furthermore, we investigated whether BPND is still robust with 61-min analysis by 
correlating DVR-1 and BPND obtained from 91-min scans with BPND obtained from 
the first 61-min analysis of the same scans (Figure 5.6). Despite the positive bias 
of BPND related to DVR-1, a good correlation was found between the parameters. 
Moreover, there was no difference in BPND estimation between 91-min and 61-min 
analysis, as the linear regression line (slope=1.0, y-intercept=0.17) is almost 
identical to the line of identity. 
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Figure 5.6 (A) Deming linear regression of BPND on DVR-1. (B) Deming linear regression of BPND 
obtained from 91-min and 61-min analysis. BPND and DVR-1 were derived by reference to cerebellum. 
A2AR occupancy by caffeine 
Caffeine pretreatment reduced tracer uptake in A2AR-rich regions in a dose-
dependent manner (Figure 5.7). Sixty one-min and 91-min analysis estimated 
comparable A2AR-occupancy, with a maximum difference of 1%, when the values 
were derived from BPND with cerebellum as reference region. The BPND and A2AR 
occupancy in striatum after 2.5, 5.0, and 10.0 mg/kg caffeine i.v. injection were 
~2.3, 1.5, 0.8, and 64%, 74%, 81%, respectively. Parietal cortex as the reference 
region failed to estimate striatal BPND at the lowest dose of 2.5 mg/kg. 
 
Figure 5.7 PET images of the transverse view of the monkey brain over 91-min scan (A) and 
corresponding TACs in striatum (B) at baseline (open circle) and after i.v. injection of caffeine at 2.5 
(triangle), 5.0 (cross) and 10.0 (closed circle) mg/kg (BPND of 6.48, 2.45, 1.80, and 1.01, respectively). 
The table shows the estimated A2AR occupancy (%) in A2AR-rich regions at the corresponding caffeine 
doses based on 91-min and 61-min analysis. The BPND for occupancy calculation was obtained from 
SRTM with cerebellum as the reference region. !""#$%&"'  ()*+, -./012/3()*+, 0456127
()*+, -./012/
 100%.  
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DISCUSSION 
We report the quantification of [11C]preladenant uptake for the imaging of A2ARs 
in the conscious monkey brain. The tracer displayed a regional uptake that is in 
agreement with the known distribution of the tracer in the brain, with highest 
uptake in putamen and caudate, and lowest uptake in cerebellum.  
The tracer kinetics can be quantified with the 2TCM in all brain regions. Regions 
devoid of receptor expression might be better fitted with 2TCM than 1TCM, 
because a small third (non-selective/metabolic) tissue compartment might exist in 
the brain which is overwhelmed by the specific compartment in receptor-rich 
regions, but not in receptor-poor regions. When the specific binding sites are 
blocked (Figure 5.2B) or in regions without receptor expression, the specific 
binding compartment disappears and the influence of this small third tissue 
compartment on tracer kinetics emerges. The presence of a small (and slow) third 
tissue compartment resulted in difficulty in estimating k4 in reference regions. In 
reference regions, the slow third tissue compartment causes TACs to level off at 
later times, leading to very small k4 values. Consequently, a 91-min acquisition 
might not be adequate and thus a longer scan might be necessary to have a better 
estimate of k4 in reference regions. In our study, cerebellar k4 could not be properly 
estimated in 2 out of 7 baseline scans and in 1 scan with complete receptor 
blockade. As the accuracy in VND estimate is essential to determine how much 
activity in total distribution volume (VT) is due to specific binding, and VND 
appeared sensitive to k4, we have studied the effect of fixing or constraining k4 on 
both VND in cerebellum and in striatum with complete receptor blockade. We found 
that a small k4 resulted in very high VND values. Therefore, we recommend to use 
the plasma input 2TCM with k4 constrained above 0.01 min-1, resulting in more 
comparable VND estimates across studies (Figure 5.3). 
With VND stabilized by restraining k4, we further estimated the specific binding in 
target regions using DVR-1, and examined the agreement between DVR-1 and 
BPND obtained from the SRTM (Figure 5.4A). The two measures correlated well 
with each other, with an average bias of +20% for BPND. However, BPND is 
favorable to DVR-1 in terms of smaller dispersion and TRV. Next, we investigated 
if BPND is still robust with a 61-min acquisition. An excellent agreement was found 
in BPND between 61- and 91-min analysis. A good positive correlation was also 
observed between 61-min BPND and 91-min DVR-1 (Figure 5.6), although the 
correlation became worse at small BPND (i.e., BPND≤1.5 (Figure 5.6A)), because 
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both methods lose the robustness of measuring specific binding in regions lacking 
specific binding sites. Taken together, our findings suggest that striatal BPND can 
be reliably quantified with a 61-min dynamic PET acquisition. A 61-min scan 
protocol was also adequate to study the A2AR-occupancy by caffeine, as a high 
degree of consistency was observed across 61- and 91-min analysis (Figure 5.7).  
Pretreatment with a blocker decreased the VT values in the reference regions by 
~30% (Figure 5.4C, for clarity, caffeine data are not presented). A reduction in VT 
in reference regions after blocker treatment was also found with 18F-labeled 
preladenant (18F-MNI-444) in a monkey study 58, but not in a rat study with 
[11C]preladenant 140. We have observed a higher plasma parent activity 
concentration after pretreatment with a blocker than at baseline. Albeit the 
difference was not statistically significant, this might still contribute to a decrease 
in VT in blocking experiments as the TACs in reference regions at baseline and in 
blocking studies are similar. Moreover, the presence of the blocking agents might 
also influence the plasma free fraction or the permeability of the blood-brain-
barrier. The former is positively correlated to VND and VT 59, the latter regulates the 
amount of intact tracer/radioactive metabolites entering the brain. The decrease in 
VT in reference regions after blocker treatment might cause a bias in BPND 
calculations in receptor occupancy studies. Further studies are needed to find out if 
such effect is species-specific, and if the reduction in VT is actually significant (it is 
not significant in our case). Amongst all investigated reference regions, cerebellum 
is favored over others in terms of low VT and robustness of BPND estimation.  
A potential pitfall in our study might be the non-negligible impact of injected mass 
of preladenant on BPND and VT, as a mass-dependent decrease in BPND was 
observed at baseline (Supplementary figure 5.2), due to variable specific activity 
of the tracer. Differences in SA between test and retest scans could account for the 
relatively high TRV (22-29%) in this study, in comparison with our rat study (TRV 
6%), in which A2AR occupancy was always <5% 140. Injection of non-negligible 
amounts of unlabeled preladenant might theoretically also have affected the A2AR 
occupancy estimation by caffeine. However, such a bias does not appear to be 
critical, as the dynamic range (BPND 0-4.5) of [11C]preladenant in striatum still 
allowed caffeine to compete with the tracer for the A2AR-binding sites in a dose-
dependent fashion. As no in vivo A2AR Bmax value is available for rhesus monkeys, 
we are unable to estimate the A2AR occupancy of preladenant at injected masses of 
3-10 nmol/kg. Regardless of possible non-negligible receptor occupancy by 
preladenant, our study demonstrates that [11C]preladenant has suitable binding 
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properties and pharmacokinetic 
profile, which warrants its 
translation to human studies. In 
human studies, issues regarding the 
injected mass dose of the tracer are 
less likely to occur, because humans 
have a 10-15 fold higher 
bodyweight than the monkeys in this 
study and modern clinical PET 
cameras require a 2-3 fold lower 
injected [11C]preladenant dose for 
proper counting statistics than the 
animal scanner applied here.  
 
CONCLUSION 
[11C]preladenant showed a regional uptake in the conscious monkey brain that is in 
accordance with the known A2AR distribution, with high uptake in striatum, and low 
uptake in cerebellum. The tracer kinetics in striatum can be well described with the 
2TCM and SRTM. A 61-min dynamic acquisition is sufficient for adequate 
assessment of BPND, whereas a scan duration of more than 91-min might be 
necessary to have a robust estimation on k4 in reference regions. Pretreatment with 
caffeine reduced the tracer uptake in A2AR-rich regions in a dose-dependent manner, 
indicating that [11C]preladenant PET is suitable to study A2AR occupancy with A2AR-
targeting molecules.  
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Supplementary figure 5.2 Relationship between 
injected mass of unlabeled preladenant and 
apparent BPND at baseline. Each monkey 
underwent 2 baseline scans with time intervals of 
~1 month. MK = monkey 
